First Patient Treated with Civacir® after Hepatitis C Induced Liver ... MarketWatch (press release) Civacir, a 10 % hepatitis C hyperimmune globulin developed and produced at Biotest Pharmaceuticals Corporation, a wholly owned subsidiary of Biotest AG, is being used in a clinical trial in North America in patients undergoing liver transplantation as ... Biotest commences phase III trial of hepatitis C therapy |
